Gilead Sciences, Inc. (GILD) vs Merck & Co., Inc. (MRK)
- Gilead Sciences, Inc. GILD 156.19 −0.75%
- Merck & Co., Inc. MRK 145.95 +0.52%
Gilead Sciences, Inc. and Merck & Co., Inc. are both Drug Manufacturers General companies. Merck & Co., Inc. is the larger, with a market value of $358.2B against $195.1B — 1.8× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; Merck & Co., Inc. trades at 117×. Gilead Sciences, Inc. grew revenue faster over the last twelve months: 5.52% against 4.64%. Merck & Co., Inc. has the higher net margin (4.77% vs −10.6%) and the higher return on invested capital (5.08% vs −4.48%). Both pay a dividend; Merck & Co., Inc. yields more (2.33% vs 2.08%). Across the 22 metrics below, Merck & Co., Inc. leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | GILD | MRK | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 79.59% | 72.97% | 72.77% |
| Operating margin | (8.20%) | 10.49% | 18.77% |
| Net margin | (10.64%) | 4.77% | 8.27% |
| Free cash flow margin | 42.50% | 24.13% | 17.18% |
| Return on equity | (20.68%) | 6.97% | 5.87% |
| Return on assets | (6.17%) | 2.57% | 2.57% |
| Return on invested capital | (4.48%) | 5.08% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack